Tissue Engineered Collagen Biomaterial Market Expected to Reach US$ 5.4 Billion by 2025

Collagen is mainly of two types. These are type I collagen and type II collagen. Type II collagens are further categorized into hydrolyzed and undenatured collagen, based on the method of production. Hydrolyzed collagen is produced by hydrolysis, which means high heat and chemicals have been employed to process it. However, undenatured type II collagen is made with little or no heating, i.e., very little processing. This undenatured collagen is made from chicken. The global tissue engineered collagen biomaterial market is likely to expand at a significant growth rate during the forecast period due to the increasing demand for collagen for various wound care, and orthopedics products owing to its properties which help to health wounds etc. is expected to drive the market during the forecast period.

The global Tissue Engineered Collagen Biomaterial Market was valued at US$ 2.2 Bn in 2016 and is estimated to reach US$ 5.4 Bn in 2025 at a CAGR of 10.4% from 2017 to 2025.

Inquire for a Sample copy of Report – http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=27938

The tissue engineered collagen biomaterial market by source type has been segmented as marine, bovine, porcine, chicken, and others. The bovine collagen segment accounted for the largest share of the global bioengineered proteins drugs market in 2016 as the price of bovine collagen is depends on the type of application and the grade types used for that specific application. Medical grade bovine collagen falls under the premium category as compared to other grades of bovine collagen. Also 3D collagen scaffold are synthesized mainly from type I bovine collagen which is driving the growth of the market whereas porcine collagen segment is anticipated to expand at a high CAGR from 2017 to 2025. The major type of collagen yielded from porcine source is type I collagen, which finds applications in wound care. Due to its high biocompatibility with human, the porcine collagen is being also used in myriad clinical field which helps to expand the segment.

The tissue engineered collagen biomaterial market by application has been segmented as wound care, orthopedics, and others. Orthopedics segment is estimated to account for highest share of the global tissue engineered collagen biomaterials market in 2016. Dominance of the segment is attributed to large number of applications such as in bone, tendon, and ligament injuries of collagen in orthopedic segment. Moreover, orthopedics segment forms an integral part of the tissue engineered collagen biomaterials market. According to studies published by the National Osteoporosis Foundation in 2014, around 54 million adults aged above 50 years are affected by low bone mass and osteoporosis in the U.S. This increases usage of collagen as bone substitutes, which in turn drives the market. Wound care segment is followed by orthopedics segment and is anticipated to expand at a significant CAGR from 2017 to 2025. According to the American Burn Association (ABA), around 1 million burn injuries occurs annually in the U.S., in which nearly 4,500 patient dies due to the injuries.

Major players operating in the global tissue engineered collagen biomaterial market includes Advanced Bio Matrix Inc., Collagen Matrix Inc., CollPlant Ltd., Collagen Matrix, Collagen Solutions Plc. Fraunhofer-Gesellschaft, Genoss Co., Ltd., Kyeron B.V., Maxigen Biotech Inc., and Medtronic.

Read Report with Complete TOC – http://www.transparencymarketresearch.com/tissue-engineered-collagen-biomaterials-market.html

Name: Rohit Bhisey
Organization: Transparency Market Research

ReleaseID: 8085